{
  "source": "PA-Med-Nec-Cosentyx.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 2196-15\nProgram Prior Authorization/Medical Necessity\nMedication Cosentyx® (secukinumab) prefilled syringe or Sensoready pen\nP&T Approval Date 5/2020, 7/2020, 11/2020, 6/2021, 7/2021, 12/2021, 2/2022, 3/2022,\n6/2022, 11/2022, 1/2023, 4/2023, 7/2023, 1/2024, 10/2024\nEffective Date 1/1/2025\n1. Background:\nCosentyx (secukinumab) is a human interleukin-17A antagonist indicated for the treatment of\nmoderate to severe plaque psoriasis in patients 6 years and older who are candidates for systemic\ntherapy or phototherapy, active psoriatic arthritis (PsA) in patients 2 years of age and older, adults\nwith active ankylosing spondylitis (AS) or active non-radiographic axial spondyloarthritis (nr-\naxSpA) with objective signs of inflammation, active enthesitis-related arthritis (ERA) in patients\n4 years of age and older, and adults with moderate to severe hidradenitis (HS).\n2. Coverage Criteriaa:\nA. Plaque Psoriasis\n1. Initial Authorization\na. Cosentyx will be approved based on all of the following criteria:\n(1) Diagnosis of moderate to severe plaque psoriasis\n-AND-\n(2) One of the following:\n(a) All of the following:\ni. Greater than or equal to 3% body surface area involvement, palmoplantar,\nfacial, genital involvement, or severe scalp psoriasis\n-AND-\nii. History of failure to one of the following topical therapies, unless\ncontraindicated or clinically significant adverse effects are experienced\n(document drug, date, and duration of trial):\na. Corticosteroids (e.g., betamethasone, clobetasol, desonide)\nb. Vitamin D analogs (e.g., calcitriol, calcipotriene)\nc. Tazarotene\nd. Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus)\ne. Anthralin\nf. Coal tar\n© 2024 UnitedHealthcare Services, Inc.\n1\n-AND-\niii. History of failure to a 3 month trial of methotrexate at maximally\nindicated dose, unless contraindicated or clinically significant adverse\neffects are experienced (document date and duration of trial)b\n-OR",
    "y of failure to a 3 month trial of methotrexate at maximally\nindicated dose, unless contraindicated or clinically significant adverse\neffects are experienced (document date and duration of trial)b\n-OR-\n(b) Patient has been previously treated with a targeted immunomodulator FDA-\napproved for the treatment of plaque psoriasis as documented by claims\nhistory or submission of medical records (Document drug, date, and duration\nof therapy) [e.g., Cimzia (certolizumab), adalimumab, Otezla (apremilast),\nSkyrizi (risankizumab), Stelara (ustekinumab), Tremfya (guselkumab),\nEnbrel (etanercept)].\n-OR-\n(c) Both of the following:\ni. Patient is currently on Cosentyx therapy as documented by claims history\nor submission of medical records (Document date and duration of\ntherapy):\n-AND-\nii. Patient has not received a manufacturer supplied sample at no cost in\nprescriber office, or any form of assistance from the Novartis sponsored\nCosentyx Connect (e.g., sample card which can be redeemed at a\npharmacy for a free supply of medication) as a means to establish as a\ncurrent user of Cosentyx*\n-AND-\n(3) Patient is not receiving Cosentyx in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),\nSimponi (golimumab), Orencia (abatacept), adalimumab, Stelara\n(ustekinumab), Skyrizi (risankizumab), Tremfya (guselkumab), Taltz\n(ixekizumab), Siliq (brodalumab), Ilumya (tildrakizumab), Xeljanz\n(tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla\n(apremilast)]\n-AND-\n(4) Prescribed by or in consultation with a dermatologist\n* Patients requesting initial authorization who were established on therapy via the receipt of a\nmanufacturer supplied sample at no cost in the prescriber’s office or any form of assistance\nfrom the Novartis sponsored Cosentyx Connect shall be required to meet initial authorization\ncriteria as if patient were new to therapy.\n© 2024 UnitedHealthcare Services, Inc.\n2\nAuthorization will be issued for 12 months.\n2. Reauthor",
    "tyx Connect shall be required to meet initial authorization\ncriteria as if patient were new to therapy.\n© 2024 UnitedHealthcare Services, Inc.\n2\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Cosentyx will be approved based on all of the following criteria:\n(1) Documentation of positive clinical response to Cosentyx therapy\n-AND-\n(2) Patient is not receiving Cosentyx in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),\nSimponi (golimumab), Orencia (abatacept), adalimumab, Stelara\n(ustekinumab), Skyrizi (risankizumab), Tremfya (guselkumab), Taltz\n(ixekizumab), Siliq (brodalumab), Ilumya (tildrakizumab), Xeljanz\n(tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla\n(apremilast)]\nAuthorization will be issued for 12 months.\nB. Psoriatic Arthritis (PsA)\n1. Initial Authorization\na. Cosentyx will be approved based on all of the following criteria:\n(1) Diagnosis of active psoriatic arthritis\n-AND-\n(2) One of the following:\n(a) History of failure to a 3 month trial of methotrexate at maximally indicated\ndose, unless contraindicated or clinically significant adverse effects are\nexperienced (document date and duration of trial)b\n-OR-\n(b) Patient has been previously treated with a targeted immunomodulator FDA-\napproved for the treatment of psoriatic arthritis as documented by claims\nhistory or submission of medical records (Document drug, date, and duration\nof therapy) [e.g., Cimzia (certolizumab), adalimumab, Simponi\n(golimumab), Stelara (ustekinumab), Tremfya (guselkumab),\nXeljanz/Xeljanz XR (tofacitinib), Otezla (apremilast), Skyrizi\n(risankizumab), Rinvoq (upadacitinib), Enbrel (etanercept)]\n-OR-\n(c) Both of the following:\n© 2024 UnitedHealthcare Services, Inc.\n3\ni. Patient is currently on Cosentyx therapy as documented by claims history\nor submission of medical records (Document date and duration of\ntherapy)\n-AND-\nii. Patient has not received a manufacturer supplied sample at no cost in\npr",
    "ntyx therapy as documented by claims history\nor submission of medical records (Document date and duration of\ntherapy)\n-AND-\nii. Patient has not received a manufacturer supplied sample at no cost in\nprescriber office, or any form of assistance from the Novartis sponsored\nCosentyx Connect (e.g., sample card which can be redeemed at a\npharmacy for a free supply of medication) as a means to establish as a\ncurrent user of Cosentyx*\n-AND-\n(3) Patient is not receiving Cosentyx in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),\nSimponi (golimumab), Orencia (abatacept), adalimumab, Stelara\n(ustekinumab), Skyrizi (risankizumab), Tremfya (guselkumab), Taltz\n(ixekizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq\n(upadacitinib), Otezla (apremilast)]\n-AND-\n(4) Prescribed by or in consultation with one of the following:\n(a) Rheumatologist\n(b) Dermatologist\n* Patients requesting initial authorization who were established on therapy via the receipt of a\nmanufacturer supplied sample at no cost in the prescriber’s office or any form of assistance\nfrom the Novartis sponsored Cosentyx Connect shall be required to meet initial authorization\ncriteria as if patient were new to therapy.\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Cosentyx will be approved based on all of the following criteria:\n(1) Documentation of positive clinical response to Cosentyx therapy\n-AND-\n(2) Patient is not receiving Cosentyx in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),\nSimponi (golimumab), Orencia (abatacept), adalimumab, Stelara\n(ustekinumab), Skyrizi (risankizumab), Tremfya (guselkumab), Taltz\n(ixekizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq\n(upadacitinib), Otezla (apremilast)]\n© 2024 UnitedHealthcare Services, Inc.\n4\nAuthorization will be issued for 12 months.\nC. Ankylosing Spondylitis (AS)\n1. Initial Authorization\na. Cosentyx will be approved b",
    "tinib), Otezla (apremilast)]\n© 2024 UnitedHealthcare Services, Inc.\n4\nAuthorization will be issued for 12 months.\nC. Ankylosing Spondylitis (AS)\n1. Initial Authorization\na. Cosentyx will be approved based on all of the following criteria:\n(1) Diagnosis of active ankylosing spondylitis\n-AND-\n(2) One of the following:\n(a) History of failure to two NSAIDs (e.g., ibuprofen, naproxen) at maximally\nindicated doses, each used for at least 4 weeks, unless contraindicated or\nclinically significant adverse effects are experienced (document drug, date,\nand duration of trials)\n-OR-\n(b) Patient has been previously treated with a targeted immunomodulator FDA-\napproved for the treatment of ankylosing spondylitis as documented by\nclaims history or submission of medical records (Document drug, date, and\nduration of therapy) [e.g., adalimumab, Simponi (golimumab),\nXeljanz/Xeljanz XR (tofacitinib), Rinvoq (upadacitinib), Enbrel\n(etanercept)].\n-OR-\n(c) Both of the following:\ni. Patient is currently on Cosentyx therapy as documented by claims history\nor submission medical records (Document date and duration of therapy):\n-AND-\nii. Patient has not received a manufacturer supplied sample at no cost in\nprescriber office, or any form of assistance from the Novartis sponsored\nCosentyx Connect (e.g., sample card which can be redeemed at a\npharmacy for a free supply of medication) as a means to establish as a\ncurrent user of Cosentyx*\n-AND-\n(3) Patient is not receiving Cosentyx in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),\nSimponi (golimumab), Orencia (abatacept), adalimumab, Xeljanz\n(tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]\n© 2024 UnitedHealthcare Services, Inc.\n5\n-AND-\n(4) Prescribed by or in consultation with a rheumatologist\n* Patients requesting initial authorization who were established on therapy via the receipt of a\nmanufacturer supplied sample at no cost in the prescriber’s office or any form of assistance\nfr",
    "ologist\n* Patients requesting initial authorization who were established on therapy via the receipt of a\nmanufacturer supplied sample at no cost in the prescriber’s office or any form of assistance\nfrom the Novartis sponsored Cosentyx Connect shall be required to meet initial authorization\ncriteria as if patient were new to therapy.\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Cosentyx will be approved based on all of the following criteria:\n(1) Documentation of positive clinical response to Cosentyx therapy\n-AND-\n(2) Patient is not receiving Cosentyx in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),\nSimponi (golimumab), Orencia (abatacept), adalimumab, Xeljanz\n(tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]\nAuthorization will be issued for 12 months.\nD. Non-radiographic Axial Spondyloarthritis\n1. Initial Authorization\na. Cosentyx will be approved based on all of the following criteria:\n(1) Diagnosis of active non-radiographic axial spondyloarthritis\n-AND-\n(2) One of the following:\n(a) History of failure to two NSAIDs (e.g., ibuprofen, naproxen) at maximally\nindicated doses, each used for at least 4 weeks, unless contraindicated or\nclinically significant adverse effects are experienced (document drug, date,\nand duration of trials)\n-OR-\n(b) Patient has been previously treated with a targeted immunomodulator\nFDA-approved for the treatment of non-radiographic axial\nspondyloarthritis as documented by claims history or submission of\n© 2024 UnitedHealthcare Services, Inc.\n6\nmedical records (Document drug, date, and duration of therapy) [e.g.,\nCimzia (certolizumab), Rinvoq (upadacitinib)]\n-OR-\n(c) Both of the following:\ni. Patient is currently on Cosentyx therapy as documented by claims history\nor submission of medical records (Document date and duration of\ntherapy)\n-AND-\nii. Patient has not received a manufacturer supplied sample at no cost in\nprescriber office, or any form of assista",
    "story\nor submission of medical records (Document date and duration of\ntherapy)\n-AND-\nii. Patient has not received a manufacturer supplied sample at no cost in\nprescriber office, or any form of assistance from the Novartis sponsored\nCosentyx Connect (e.g., sample card which can be redeemed at a\npharmacy for a free supply of medication) as a means to establish as a\ncurrent user of Cosentyx*\n-AND-\n(3) Patient is not receiving Cosentyx in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),\nSimponi (golimumab), Orencia (abatacept), adalimumab, Xeljanz\n(tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]\n-AND-\n(4) Prescribed by or in consultation with a rheumatologist\n* Patients requesting initial authorization who were established on therapy via the receipt of a\nmanufacturer supplied sample at no cost in the prescriber’s office or any form of assistance\nfrom the Novartis sponsored Cosentyx Connect shall be required to meet initial authorization\ncriteria as if patient were new to therapy.\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Cosentyx will be approved based on all of the following criteria:\n(1) Documentation of positive clinical response to Cosentyx therapy\n-AND-\n(2) Patient is not receiving Cosentyx in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),\nSimponi (golimumab), Orencia (abatacept), adalimumab, Xeljanz\n(tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]\n© 2024 UnitedHealthcare Services, Inc.\n7\nAuthorization will be issued for 12 months.\nE. Enthesitis-Related Arthritis\n1. Initial Authorization\na. Cosentyx will be approved based on all of the following criteria:\n(1) Diagnosis of active enthesitis-related arthritis\n-AND-\n(2) One of the following:\n(a) History of failure to two NSAIDs (e.g., ibuprofen, naproxen) at maximally\nindicated doses, each used for at least 4 weeks, unless contraindicated or\nclinically significant ",
    ") One of the following:\n(a) History of failure to two NSAIDs (e.g., ibuprofen, naproxen) at maximally\nindicated doses, each used for at least 4 weeks, unless contraindicated or\nclinically significant adverse effects are experienced (document drug, date,\nand duration of trials)\n-OR-\n(b) Both of the following:\ni. Patient is currently on Cosentyx therapy as documented by claims history\nor submission of medical records (Document date and duration of\ntherapy)\n-AND-\nii. Patient has not received a manufacturer supplied sample at no cost in\nprescriber office, or any form of assistance from the Novartis sponsored\nCosentyx Connect (e.g., sample card which can be redeemed at a\npharmacy for a free supply of medication) as a means to establish as a\ncurrent user of Cosentyx*\n-AND-\n(3) Patient is not receiving Cosentyx in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), adalimumab, Cimzia\n(certolizumab), Simponi (golimumab), Xeljanz (tofacitinib), Rinvoq\n(upadacitinib)]\n-AND-\n(4) Prescribed by or in consultation with a rheumatologist\n* Patients requesting initial authorization who were established on therapy via the receipt of a\nmanufacturer supplied sample at no cost in the prescriber’s office or any form of assistance\nfrom the Novartis sponsored Cosentyx Connect shall be required to meet initial authorization\ncriteria as if patient were new to therapy.\n© 2024 UnitedHealthcare Services, Inc.\n8\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Cosentyx will be approved based on all of the following criteria:\n(1) Documentation of positive clinical response to Cosentyx therapy\n-AND-\n(2) Patient is not receiving Cosentyx in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), adalimumab, Cimzia\n(certolizumab), Simponi (golimumab), Xeljanz (tofacitinib), Rinvoq\n(upadacitinib)]\nAuthorization will be issued for 12 months.\nF. Hidradenitis Suppurativa (HS)\n1. Initial Authorization\na. Cosentyx will be approved based on a",
    "(golimumab), Xeljanz (tofacitinib), Rinvoq\n(upadacitinib)]\nAuthorization will be issued for 12 months.\nF. Hidradenitis Suppurativa (HS)\n1. Initial Authorization\na. Cosentyx will be approved based on all of the following criteria:\n(1) Diagnosis of moderate to severe hidradenitis suppurativa (i.e., Hurley Stage\nII or III)\n-AND-\n(2) One of the following:\n(a) History of failure to at least one oral antibiotic (e.g., doxycycline,\nclindamycin, rifampin) at maximally indicated doses, unless contraindicated\nor clinically significant adverse effects are experienced (document drug,\ndate, and duration of trial)\n-OR-\n(b) Both of the following:\ni. Patient is currently on Cosentyx therapy as documented by claims history\nor submission of medical records (Document date and duration of\ntherapy):\n-AND-\nii. Patient has not received a manufacturer supplied sample at no cost in the\nprescriber’s office, or any form of assistance from a Novartis sponsored\nprogram (e.g., sample card which can be redeemed at a pharmacy for a\n© 2024 UnitedHealthcare Services, Inc.\n9\nfree supply of medication) as a means to establish as a current user of\nCosentyx*\n-AND-\n(3) Patient is not receiving Cosentyx in combination with another targeted\nimmunomodulator [e.g., adalimumab, Enbrel (etanercept), Cimzia\n(certolizumab), Simponi (golimumab), Orencia (abatacept), Xeljanz\n(tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]\n-AND-\n(4) Prescribed by or in consultation with a dermatologist\n* Patients requesting initial authorization who were established on therapy via the\nreceipt of a manufacturer supplied sample at no cost in the prescriber’s office or any\nform of assistance from a Novartis sponsored program shall be required to meet initial\nauthorization criteria as if patient were new to therapy.\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Cosentyx will be approved based on all of the following criteria:\n(1) Documentation of positive clinical response to Cosentyx therapy.\n-AND-\n(2",
    "tion will be issued for 12 months.\n2. Reauthorization\na. Cosentyx will be approved based on all of the following criteria:\n(1) Documentation of positive clinical response to Cosentyx therapy.\n-AND-\n(2) Patient is not receiving Cosentyx in combination with another targeted\nimmunomodulator [e.g., adalimumab, Enbrel (etanercept), Cimzia\n(certolizumab), Simponi (golimumab), Orencia (abatacept), Xeljanz\n(tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\nb For Connecticut, Kentucky and Mississippi business only a 30-day trial will be required.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place.\n© 2024 UnitedHealthcare Services, Inc.\n10\n4. Reference:\n1. Cosentyx [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp.; October 2023.\n2. Ward MM, Deodhar, A, Gensler, LS, et al. 2019 Update of the American College of\nRheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment\nNetwork Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic\nAxial Spondyloarthritis. Arthritis & Rheumatology. 2019; 71(10): 1599-1613.\n3. Yu, DT, van Tubergen A. Treatment of axial spondyloarthritis (ankylosing spondylitis and\nnonradiographic axial spondyloarthritis) in adults. Sieper, J (Ed). UpToDate. Waltham, MA:\nUpToDate Inc. http://www.uptodate.com (Accessed on October 10, 2019.)\n4. Singh, JA, Guyatt, G, et al. 2018 American College of Rheumatology/National Psoriasis\nFoundation Guide",
    ". UpToDate. Waltham, MA:\nUpToDate Inc. http://www.uptodate.com (Accessed on October 10, 2019.)\n4. Singh, JA, Guyatt, G, et al. 2018 American College of Rheumatology/National Psoriasis\nFoundation Guideline for the Treatment of Psoriatic Arthritis. Arthritis & Rheumatology. 2019;\n71(1): 5-32.\n5. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and\npsoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of\npsoriasis with biologics. J Am Acad Dermatol 2008; 58(5):826-50.\n6. Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis\nand psoriatic arthritis. Psoriatic arthritis: Overview and guidelines of care for treatment with an\nemphasis on the biologics. J Am Acad Dermatol 2008;58(5):851-64.\n7. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and\npsoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis\nwith topical therapies. J Am Acad Dermatol 2009;60(4):643-59.\n8. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and\npsoriatic arthritis. Guidelines of care for the treatment of psoriasis with phototherapy and\nphotochemotherapy. J Am Acad Dermatol 2010;62(1):114-35.\n9. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and\npsoriatic arthritis. Guidelines of care for the management and treatment of psoriasis with\ntraditional systemic agents. J Am Acad Dermatol 2009;61(3):451-85.\n10. Nast A, et al; European S3-Guidelines on the systemic treatment of psoriasis vulgaris – update\n2015 – short version – EFF in cooperation with EADV and IPC, J Eur Acad Derm Venereol\n2015;29:2277-94.\n11. Menter A, Korman NJ, Elmets CA,Feldman SR, Gelfand JM, Gordon KB, Guidelines of care for\nthe management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment\nof psoriasis and psoriatic arthr",
    "lmets CA,Feldman SR, Gelfand JM, Gordon KB, Guidelines of care for\nthe management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment\nof psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J\nAm Acad Dermatol. 2011 Jul;65(1):137-74.\n12. Gossec L, et al; European League Against Rheumatism (EULAR) recommendations for the\nmanagement of psoriatic arthritis with pharmacological therapies: 2015 update, Ann Rheum Dis\n2016;75:499-510.\n13. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management\nand treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80:1029-72.\n14. Bodemer C, Kaszuba A, Kingo K, et al. Secukinumab demonstrates high efficacy and a\nfavourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week\nresults from a Phase 3 double-blind randomized, controlled trial. J Eur Acad Dermatol Venereol.\n2021;35(4):938-947. doi:10.1111/jdv.17002\nProgram Prior Authorization/Medical Necessity - Cosentyx (secukinumab)\nChange Control\n5/2020 New program.\n© 2024 UnitedHealthcare Services, Inc.\n11\n7/2020 Updated background and criteria to include new indication for non-\nradiographic axial spondyloarthritis. Clarified documentation\nrequirements. Updated references.\n11/2020 Added Tremfya as a step therapy medication for psoriatic arthritis.\nRevised psoriasis step therapy medications due to expanded indication\nfor use of Stelara in patients 6 years and older.\n6/2021 Removed prescriber requirement from reauthorization criteria. Added\ncoverage criteria for patients previously treated with a biologic\nDMARD. Added clarification that submission of medical records is\nrequired documenting current therapy with Cosenyx in order to bypass\nstep if claim history not available.\n7/2021 Updated background to include expanded indication for moderate to\nsevere plaque psoriasis to pediatric patients 6 years and older. Updated\nreferences.\n12/2021 Updated ",
    "im history not available.\n7/2021 Updated background to include expanded indication for moderate to\nsevere plaque psoriasis to pediatric patients 6 years and older. Updated\nreferences.\n12/2021 Updated the following with no change to clinical intent: updated\nconventional DMARD bypass language for psoriatic arthritis and\npsoriasis, removed “biologic” from required preferred product criteria\nlanguage, updated age requirement language and updated CT/KY\nfootnote.\n2/2022 Updated background and clinical criteria with new indication for ERA.\nUpdated formatting of clinical criteria for nr-axSpA. Updated\nreference.\n3/2022 Added Skyrizi as a preferred drug for active psoriatic arthritis.\nClarified criteria for non-radiographic axial spondyloarthritis that\npatient must still have a history of failure, contraindication, or\nintolerance to Cimzia (certolizumab) whether they were previously\ntreated with a DMARD or have failed two NSAIDs.\n6/2022 Added Rinvoq and Xeljanz to step therapy medication for ankylosing\nspondylitis and psoriatic arthritis. Added Rinvoq and/or Xeljanz to\nexamples where appropriate. Added Mississippi to state mandate\nfootnote.\n11/2022 Added Enbrel as a preferred product step option for AS, PsO, and PsA.\nAdded Enbrel as an example where appropriate. Added Rinvoq as a\nstep option for non-radiographic axial spondyloarthritis. Added targeted\nsynthetic to DMARD bypass for non-radiographic axial\nspondyloarthritis.\n1/2023 Updated step therapy requirements to Humira or Amjevita. Updated\nlisted examples from Humira to adalimumab.\n4/2023 Updated step therapy requirement from Humira or Amjevita to one of\nthe preferred adalimumab products and added the footnote “For a list of\npreferred adalimumab products please reference drug coverage tools.”\n7/2023 Updated not receiving in combination language to targeted\nimmunomodulator and updated examples.\n1/2024 Added coverage criteria for new indication for Hidradenitis Suppurativa\n(HS). Updated state mandate footnote. Updated backg",
    "ombination language to targeted\nimmunomodulator and updated examples.\n1/2024 Added coverage criteria for new indication for Hidradenitis Suppurativa\n(HS). Updated state mandate footnote. Updated background and\nreference.\n10/2024 Removed all step therapy requirements through preferred products.\nRemoved adalimumab footnote.\n© 2024 UnitedHealthcare Services, Inc.\n12"
  ]
}